The effect of soy-derived isoflavones over hot flushes, menopausal symptoms and mood in climacteric women with increased body mass index

Gynecological Endocrinology

Volumn 27, Issue 5, 2011, Pages 307-313

  Chedraui, Peter ^a,b   San Miguel, Glenda ^a   Schwager, Gino ^a  

^a Instituto Para la Salud de la Mujer   (Ecuador)

^b UNIVERSIDAD CATÓLICA DE SANTIAGO DE GUAYAQUIL   (Ecuador)

Author keywords

hot flushes; increased body weight; menopausal symptoms; mood; Soy isoflavones

Indexed keywords

CLIMASOY; ISOFLAVONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL EVALUATION; DIET SUPPLEMENTATION; FEMALE; HAMILTON SCALE; HOT FLUSH; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE RATING SCALE; MOOD DISORDER; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SOYBEAN; TREATMENT DURATION;

ADULT; AFFECT; BODY MASS INDEX; DIETARY SUPPLEMENTS; FEMALE; HOT FLASHES; HUMANS; ISOFLAVONES; MENOPAUSE; MIDDLE AGED; SOYBEANS;

EID: 79953827609     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.490614     Document Type: Article

References (60)

1. Bhavnani BR, Strickler RC. Menopausal hormone therapy. J Obstet Gynaecol Can 2005;27:137-162.
2. Castelo-Branco C, Rostro F. Management of menopause. Minerva Ginecol 2006;58:137-152. (Pubitemid 43724811)
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. (Pubitemid 34761611)
4. Blumel JE, Castelo-Branco C, Chedraui PA, Binfa L, Dowlani B, Gomez MS, Sarra S. Patients' and clinicians' attitudes after the Women's Health Initiative study. Menopause 2004;11:57-61. (Pubitemid 40362199)
5. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-1232. (Pubitemid 37518400)
6. Lazar F Jr, Costa-Paiva L, Morais SS, Pedro AO, Pinto-Neto AM. The attitude of gynecologists in Sao Paulo, Brazil 3 years after the Women's Health Initiative study. Maturitas 2007;56:129-141.
7. Nassar AH, Abd Essamad HM, Awwad JT, Khoury NG, Usta IM. Gynecologists' attitudes towards hormone therapy in the post 'Women's Health Initiative' study era. Maturitas 2005;52:18-25.
8. Miksicek RJ. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 1993;44:37-43. (Pubitemid 23230457)
9. Miksicek RJ. Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. J Steroid Biochem Mol Biol 1994;49:153-160. (Pubitemid 24237089)
10. Dornstauder E, Jisa E, Unterrieder I, Krenn L, Kubelka W, Jungbauer A. Estrogenic activity of two standardized red clover extracts (menoflavon) intended for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2001;78:67-75. (Pubitemid 32786788)
11. Rees M. Alternative treatments for the menopause. Best Pract Res Clin Obstet Gynaecol 2009;23:151-161.
12. Nedrow A, Miller J, Walker M, Nygren P, Huffman LH, Nelson HD. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 2006;166:1453-1465. (Pubitemid 44125864)
13. Cheema D, Coomarasamy A, El-Toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. Arch Gynecol Obstet 2007;276:463-469. (Pubitemid 47415761)
14. Bitto A, Altavilla D, Bonaiuto A, Polito F, Minutoli L, Di Stefano V, Giuliani D, Guarini S, Arcoraci V, Squadrito F. Effects of aglycone genistein in a rat experimental model of postmenopausal metabolic syndrome. J Endocrinol 2009;200:367-376.
15. Farina HG, Pomies M, Alonso DF, Gomez DE. Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep 2006;16:885-891.
16. Gallo D, Zannoni GF, Apollonio P, Martinelli E, Ferlini C, Passetti G, Riva A, Morazzoni P, Bombardelli E, Scambia G. Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile. Menopause 2005;12:589-600. (Pubitemid 41363742)
17. Hidalgo LA, Chedraui PA, Morocho N, Alvarado M, Chavez D, Huc A. The metabolic syndrome among postmenopausal women in Ecuador. Gynecol Endocrinol 2006;22:447-454. (Pubitemid 44521835)
18. Chedraui P, Pérez-López FR, Morales B, Hidalgo L. Depressive symptoms among climacteric women are related to menopausal symptom intensity and partner factors. Climacteric 2009;12:395-403.
19. Chedraui P, Aguirre W, Hidalgo L, Fayad L. Assessing menopausal symptoms among healthy middle aged women with the Menopause Rating Scale. Maturitas 2007;57:271-278. (Pubitemid 46891702)
20. Sierra B, Hidalgo LA, Chedraui PA. Measuring climacteric symptoms in an Ecuadorian population with the Greene Climacteric Scale. Maturitas 2005;51:236-245. (Pubitemid 40835944)
21. Chedraui P, Hidalgo L, Chavez D, Morocho N, Alvarado M, Huc A. Quality of life among postmenopausal Ecuadorian women participating in a metabolic syndrome screening program. Maturitas 2007;56:45-53. (Pubitemid 44895637)
22. Hidalgo LA, Chedraui PA, Morocho N, Ross S, San Miguel G. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study. Gynecol Endocrinol 2005;21:257-264. (Pubitemid 43041746)
23. http://www.menopause-rating-scale.info/documents/Ref-Values-CountrGr.pdf. Last accessed 20 June 2008.
24. Heinemann LA, Potthoff P, Schneider HP. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes 2003;1:28.
25. Aedo S, Porcile A, Irribarra C. Calidad de vida relacionada con el climaterio en una población Chilena de mujeres saludables. Rev Chil Obstet Ginecol 2006;71:402-409.
26. Chedraui P, Blümel JE, Baron G, Belzares E, Bencosme A, Calle A, Danckers L, Espinoza MT, Flores D, Gomez G, et al. Impaired quality of life among middle aged women: A multicentre Latin American study. Maturitas 2008;61:323-329.
27. http://www.menopause-rating-scale.info/ Last accessed 30 July 2008.
28. Heinemann LA, DoMinh T, Strelow F, Gerbsch S, Schnitker J, Schneider HP. The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcomes 2004;2:67.
29. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
30. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1989;45:742-747.
31. Ramos-Brieva JA, Cordero-Villafafila A. A new validation of the Hamilton Rating Scale for Depression. J Psychiatric Res 1988;22:21-28.
32. American Psychiatric Association. Handbook of psychiatric measures. Washington, DC: American Psychiatric Association; 2000.
33. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods N. Executive summary: stages of Reproductive Aging Workshop (STRAW). Climacteric 2001;4:267-272. (Pubitemid 34002968)
34. Schonberg MA,Wee CC. Menopausal symptom management and prevention counseling after the Women's Health Initiative among women seen in an internal medicine practice. J Womens Health (Larchmt) 2005;14:507-514.
35. Pérez-Lopez FR, Chedraui P, Gilbert JJ, Pérez-Roncero G. Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women's Health Initiative era. Fertil Steril 2009;64:1171-1186.
36. Ferrari A. Soy extract phytoestrogens with high dose of isoflavones for menopausal symptoms. J Obstet Gynaecol Res 2009;35:1083-1090.
37. Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas 2007;58:249-258. (Pubitemid 350103531)
38. Petri Nahas E, Nahás Neto J, De Luca L, Traiman P, Pontes A, Dalben I. Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy. Maturitas 2004;48:372-380. (Pubitemid 38993251)
39. Blumel JE, Castelo-Branco C, Rocangliolo ME, Bifa L, Tacla X, Mamani L. Changes in body mass index around menopause: a population study of Chilean woman. Menopause 2001;8:239-244. (Pubitemid 32645956)
40. Nachtigall LE, Baber RJ, Barentsen R, Durand N, Panay N, Pitkin J, van de Weijer PH, Wysocki S. Complementary and hormonal therapy for vasomotor symptom relief: a conservative clinical approach. J Obstet Gynaecol Can 2006 2006;28:279-289.
41. Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A. Efficacy of isoflavones in relieving vasomotor menopausal symptoms - A systematic review. Mol Nutr Food Res 2009;53:1084-1097.
42. Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007;4:CD001395.
43. Gambacciani M, Pepe A. Vasomotor symptoms and cardiovascular risk. Climacteric 2009;12:32-35.
44. Pinkerton JV, Stovall DW. Is there an association between vasomotor symptoms and both low bone density and cardiovascular risk? Menopause 2009;16:219-223.
45. Chedraui P, Hidalgo L, Chavez D, Morocho N, Alvarado M, Huc A. Menopausal symptoms and associated risk factors among postmenopausal women screened for the metabolic syndrome. Arch Gynecol Obstet 2007;275:161-168. (Pubitemid 46221269)
46. Chedraui P, San Miguel G, Hidalgo L, Morocho N, Ross S. Effect of Trifolium pratense-derived isoflavones on the lipid profile of postmenopausal women with increased body mass index. Gynecol Endocrinol 2008;24:620-624.
47. Juliá-Mollá MD, García-Sánchez Y, Romeu Sarrió A, Pérez-López FR. Cimicifuga racemosa treatment and health related quality of life in postmenopausal Spanish women. Gynecol Endocrinol 2009;25:21-26.
48. Pérez-López FR, Chedraui P, Haya J, Cuadros JL. Effects of the Mediterranean diet on longevity and age-related morbid conditions. Maturitas 2009;64:67-79.
49. Llaneza P, Gonzalez C, Fernandez-Iñarrea J, Alonso A, Diaz-Fernandez MJ, Arnott I, Ferrer-Barriendos J. Soy isoflavones, Mediterranean diet, and physical exercise in postmenopausal women with insulin resistance. Menopause 2010;17:372-378.
50. Charles C, Yuskavage J, Carlson O, John M, Tagalicud AS, MaggioM, Muller DC, Egan J, Basaria S. Effects of high-dose isoflavones on metabolic and inflammatory markers in healthy postmenopausal women. Menopause 2009;16:395-400.
51. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29:85-96.
52. Barry KL, Fleming MF, Manwell LB, Copeland LA, Appel S. Prevalence of and factors associated with current and lifetime depression in older adult primary care patients. Fam Med 1998;30:366-371. (Pubitemid 28267673)
53. Craig MC, Murphy DG. Estrogen: effects on normal brain function and neuropsychiatric disorders. Climacteric 2007;10:97-104. (Pubitemid 47450834)
54. Joffe H, Hall JE, Soares CN, Hennen J, Reilly CJ, Carlson K, Cohen LS. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002;9:392-398. (Pubitemid 36706332)
55. Juang KD, Wang SJ, Lu SR, Lee SJ, Fuh JL. Hot flashes are associated with psychological symptoms of anxiety and depression in peri- and post- but not premenopausal women. Maturitas 2005;52:119-126.
56. Chedraui P, Morales B, Hidalgo L. Depression and related risk factors among climacteric women Climacteric 2008;11: 125.
57. Lipovac M, Chedraui P, Gruenhut C, Gocan A, Stammler M, Imhof M. Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts. Maturitas 2010;65:258-261.
58. Bryant M, Cassidy A, Hill C, Powell J, Talbot D, Dye L. Effect of consumption of soy isoflavones on behavioural, somatic and affective symptoms in women with premenstrual syndrome. Br J Nutr 2005;93:731-739. (Pubitemid 43906359)
59. de Sousa-Muñoz RL, Filizola RG. Efficacy of soy isoflavones for depressive symptoms of the climacteric syndrome. Maturitas 2009;63:89-93.
60. Bu L, Lephart ED. Soy isoflavones modulate the expression of BAD and neuron-specific beta III tubulin in male rat brain. Neurosci Lett 2005;385:153-157.